Assay
Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Nexgel, Inc.NXGLW · healthcare | |
|---|---|
| Grade |  Cmiddle fifth of 371 graded peers; percentile 52.8, sampling error 2.5 points; lower is stronger |
| Rank | 196 of 371 |
| Profitability | Cpercentile 48.7 |
| Solvency | Dpercentile 68.9 |
| Growth and financing | Bpercentile 29.3 |
| Reliability | 0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| Peer failure rate | 0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | under $12.5M assetstotal assets $10.5M[1] |
| Standard universe | insiderevenue above $1M and assets above $10M[1-2] |
| Warnings | late filernot computable: dilution, short runway, distress, fortress balance sheet |
| Inputs computable | 7 of 14 |
| Graded from | filings received through Apr 30, 2026162 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $0.012026-09-25; market equity $0; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 31, 2026; the document on sec.gov.
We were incorporated in Delaware on January 13, 2009. We manufacture high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. We specialize in custom gels by capitalizing on proprietary manufacturing technologies. We distribute our products as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products. We also have a line of branded consumer products sold direct to consumers and custom and white label opportunities, which focuses on combining our gels with proprietary branded products and white label opportunities.
Warnings [top]
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
The Fourteen Inputs [top]
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 48.7 | |||||||
| Gross profitability | 43.1% | [1,3] | 32.2% | 28.4 | 372 | 2025-12-31 | |
| Return on invested capital | not computable | 9.3% | |||||
| required facts have no common fiscal period end | |||||||
| Accruals ratio | (15.8%) | [1,4-6] | (6.6%) | 28.1 | 811 | 2025-12-31 | |
| Gross margin stability, five years | 14.6 pts | [2-3,7-14] | 2.8 pts | 89.5 | 243 | 2025-12-31 | |
| Solvency, sleeve percentile 68.9 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| firm-wide XBRL shares cannot be assigned to one ticker class | |||||||
| Altman Z double-prime | (6.99) | [1,15-20] | (0.31) | 56.1 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| required facts have no common fiscal period end | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| interest expense must exceed $100,000 | |||||||
| Current ratio | 1.47x | [15-16] | 2.96x | 81.8 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 29.3 | |||||||
| Revenue growth, three-year compound | 77.3% | [2,8,10,12] | 10.0% | 7.9 | 415 | 2025-12-31 | |
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| required facts have no common fiscal period end | |||||||
| Asset growth, three years | 0.3% | [1,6,21-22] | 2.1% | 50.7 | 704 | 2025-12-31 | |
| Net share issuance, one year | not computable | 2.5% | |||||
| firm-wide XBRL shares cannot be assigned to one ticker class | |||||||
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Sleeves are equal-weighted; within a sleeve each computable input carries equal weight. Composite -0.021; sampling error 2.5 percentile points on 371 peers.
Among 371 Peers [top]
Composite score of every graded peer, smoothed. Vertical rules are the letter band edges at the 20th, 40th, 60th and 80th percentiles. Small dots are the six largest peers by market equity.
| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 192 | Recursion Pharmaceuticals, Inc. (RXRX) Recursion Pharmaceuticals, Inc. (RXRX) Cmiddle fifth; percentile 51.6 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $2.1B; last close $3.94 Warnings: dilution, fortress balance sheet; 8 of 14 inputs | 51.6 | C | dilution, fortress balance sheet |
| 193 | Haemonetics Corp. (HAE) Haemonetics Corp. (HAE) Cmiddle fifth; percentile 51.9 NYSE · Surgical & Medical Instruments & Apparatus market equity $5.4B; last close $119.53 No active warnings; 11 of 14 inputs | 51.9 | C | |
| 194 | Solventum Corp. (SOLV) Solventum Corp. (SOLV) Cmiddle fifth; percentile 52.2 NYSE · Surgical & Medical Instruments & Apparatus market equity $14.7B; last close $86.37 No active warnings; 8 of 14 inputs | 52.2 | C | |
| 195 | Aveanna Healthcare Holdings, Inc. (AVAH) Aveanna Healthcare Holdings, Inc. (AVAH) Cmiddle fifth; percentile 52.4 Nasdaq · Services-Home Health Care Services market equity $2.7B; last close $12.24 No active warnings; 10 of 14 inputs | 52.4 | C | |
| 196 | Nexgel, Inc. (NXGL) Nexgel, Inc. (NXGL) Cmiddle fifth; percentile 52.8 Nasdaq · Surgical & Medical Instruments & Apparatus last close $0.15 Warnings: late filer; 7 of 14 inputs | 52.8 | C | late filer |
| 197 | Nexgel, Inc. (NXGLW) Nexgel, Inc. (NXGLW) Cmiddle fifth; percentile 52.8 Nasdaq · Surgical & Medical Instruments & Apparatus last close $0.01 Warnings: late filer; 7 of 14 inputs | 52.8 | C | late filer |
| 198 | Perrigo Co. plc (PRGO) Perrigo Co. plc (PRGO) Cmiddle fifth; percentile 53.2 NYSE · Pharmaceutical Preparations market equity $2.0B; last close $14.50 No active warnings; 9 of 14 inputs | 53.2 | C | |
| 199 | Sotera Health Co. (SHC) Sotera Health Co. (SHC) Cmiddle fifth; percentile 53.5 Nasdaq · Services-Misc Health & Allied Services, NEC market equity $5.1B; last close $17.84 No active warnings; 8 of 14 inputs | 53.5 | C | |
| 200 | Universal Health Services Inc. (UHS) Universal Health Services Inc. (UHS) Cmiddle fifth; percentile 53.8 NYSE · Services-General Medical & Surgical Hospitals, NEC last close $175.66 No active warnings; 9 of 14 inputs | 53.8 | C | |
| 201 | Roivant Sciences Ltd. (ROIV) Roivant Sciences Ltd. (ROIV) Cmiddle fifth; percentile 54.1 Nasdaq · Pharmaceutical Preparations market equity $24.7B; last close $34.22 Warnings: fortress balance sheet; 7 of 14 inputs | 54.1 | C | fortress balance sheet |
| 202 | Emergent BioSolutions Inc. (EBS) Emergent BioSolutions Inc. (EBS) Cmiddle fifth; percentile 54.3 NYSE · Pharmaceutical Preparations market equity $349.2M; last close $6.82 No active warnings; 10 of 14 inputs | 54.3 | C |
| Peer policy | Letter | Percentile | Peers |
|---|---|---|---|
| all graded filers, equal sleeves | C | 50.3 | 2204 |
| sector peers, equal sleeves (the grade) | C | 52.8 | 371 |
| same exchange, equal sleeves | C | 51.0 | 1219 |
| sector peers, equal inputs | C | 53.4 | 371 |
Each letter is one fifth of the 371 graded peers, about 74 companies. A boundary letter (A/B, B/C, C/D, D/E) marks a percentile within one sampling error of a band edge.
What the Price Implies [top]
Market measures at the 2026-09-25 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (94.0%) | 8.0% | 1 | hotter than 1 of 100 peers |
| Distance from 52-week high | (97.3%) | (31.4%) | 1 | closer to its high than 1 of 100 peers |
| EBIT to enterprise value | not computable | (1.5%) | required accounting or market input is missing | |
| Free cash flow yield | not computable | (1.0%) | required accounting or market input is missing | |
| Book value to price | not computable | 0.28 | required accounting or market input is missing | |
| Sales to price | not computable | 0.31 | required accounting or market input is missing | |
| Composite equity issuance, five years | not computable | 20.3% | required accounting or market input is missing | |
| Relative strength against the sector, log excess return | (3.03) | (0.14) | 1 | ahead of 1 of 100 peers |
Inputs: EBIT -$3.4M; free cash flow -$1.4M; book equity $4.9M; sales $11.4M; debt $563,000; cash $938,000[23].
Diagnostics [top]
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (27.3%) | ✗ fail[4,6] |
| Operating cash flow above zero | -$1.3M | ✗ fail[5] |
| Return on assets improved | 5.6 pts | ✓ pass[4,6,21,24] |
| Operating cash flow exceeds net income | $1.7M | ✓ pass[4-5] |
| Long-term leverage fell | (1.1 pts) | ✓ pass[1,6,21,25-26] |
| Current ratio improved | (60.3 pts) | ✗ fail[15-16,27-28] |
| No new shares issued | n/a | |
| Gross margin improved | 7.9 pts | ✓ pass[2-3,7-8] |
| Asset turnover improved | 16.7 pts | ✓ pass[2,6,8,21] |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | n/a |
| Operating cash flow, four quarters | n/a[5,29-32] |
| Months of runway | not finite |
| cash is missing at the end of the latest cash-flow quarter | |
| Late filings, two years | 1 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 53 |
| 10-Q received Aug 17, 2026 | |
| Median daily dollar volume | $3 |
| 63 sessions | |
| Days since newest grade input | 162 |
Downloads [top]
|
Sources [top]
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $10.5M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $11.4M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 3 | gross profit | us-gaap:GrossProfit | $4.5M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 4 | net income | us-gaap:NetIncomeLoss | -$3.0M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$1.3M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 6 | assets | us-gaap:Assets | $11.0M | 2024-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 7 | gross profit | us-gaap:GrossProfit | $2.7M | 2024-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 8 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $8.7M | 2024-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 9 | gross profit | us-gaap:GrossProfit | $374,000 | 2023-12-31 | 2025-03-27 | 10-K | filing · viewer · series |
| 10 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $4.1M | 2023-12-31 | 2025-03-27 | 10-K | filing · viewer · series |
| 11 | gross profit | us-gaap:GrossProfit | $256,000 | 2022-12-31 | 2024-04-10 | 10-K | filing · viewer · series |
| 12 | revenue | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax | $2.0M | 2022-12-31 | 2024-04-10 | 10-K | filing · viewer · series |
| 13 | gross profit | us-gaap:GrossProfit | $8,000 | 2021-12-31 | 2023-03-28 | 10-K | filing · viewer · series |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax | $1.6M | 2021-12-31 | 2023-03-28 | 10-K | filing · viewer · series |
| 15 | current assets | us-gaap:AssetsCurrent | $4.3M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $3.0M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 17 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$21.0M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 18 | operating income | us-gaap:OperatingIncomeLoss | -$3.4M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 19 | book equity | us-gaap:StockholdersEquity | $4.5M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 20 | liabilities | us-gaap:Liabilities | $5.6M | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 21 | assets | us-gaap:Assets | $10.0M | 2023-12-31 | 2025-03-27 | 10-K | filing · viewer · series |
| 22 | assets | us-gaap:Assets | $10.4M | 2022-12-31 | 2024-04-10 | 10-K | filing · viewer · series |
| 23 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 9,747,663 | 2026-08-14 | 2026-08-17 | 10-Q | filing · viewer · series |
| 24 | net income | us-gaap:NetIncomeLoss | -$3.3M | 2024-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 25 | long term debt | us-gaap:LongTermDebt | $588,000 | 2025-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 26 | long term debt | us-gaap:LongTermDebt | $685,000 | 2024-12-31 | 2025-03-27 | 10-K | filing · viewer · series |
| 27 | current assets | us-gaap:AssetsCurrent | $5.1M | 2024-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 28 | current liabilities | us-gaap:LiabilitiesCurrent | $2.5M | 2024-12-31 | 2026-03-31 | 10-K | filing · viewer · series |
| 29 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$2.7M | 2026-06-30 | 2026-08-17 | 10-Q | filing · viewer · series |
| 30 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$504,000 | 2026-03-31 | 2026-05-14 | 10-Q | filing · viewer · series |
| 31 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$1.6M | 2025-09-30 | 2025-11-12 | 10-Q | filing · viewer · series |
| 32 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$807,000 | 2025-06-30 | 2026-08-17 | 10-Q | filing · viewer · series |
Limitations [top]
Grade boundary. Percentile 52.8 is 7.2 points from the nearest band edge; sampling error is 2.5 points.
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
